Method to keep track of cancer comorbidities is successful; may help cancer research

September 16, 2003

St. Louis, Sept. 16, 2003 -- Many cancer patients have other diseases, and those ailments can influence their chance of survival and response to treatment. Although physicians take a person's overall health into account when determining prognosis and making treatment recommendations, that information is not recorded in tumor registries and used in medical research, according to Jay F. Piccirillo, M.D., associate professor of otolaryngology and medicine at Washington University School of Medicine in St. Louis.

Piccirillo and his team have developed a program to train cancer registrars to track patients' other diseases, called comorbidities. Five centers around the country, including the Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital, have been learning and implementing the program since 1999. Piccirillo discussed his group's methods today at the Centers for Disease Control and Prevention's 2003 Cancer Conference in Atlanta. At the same conference, another team member and research assistant, Irene Costas, outlined findings from the first five centers. "Comorbidity is increasingly recognized as an important feature of the patient with cancer,"

Piccirillo explains. "Some people are skeptical about whether it's practical to train registrars to code comorbidity information, but our research shows that the method we've developed is easy for them to learn and to do well."

He believes recording comorbidities will provide more comprehensive profiles of patients and improve cancer research. For example, a patient's chance of survival depends not only on his or her cancer type and severity but also on the patient's other health problems. Therefore, in comparing the success of two treatments, it may not be accurate to simply compare all cancer patients undergoing treatment. Similarly, comorbidities can cloud quality-of-care assessments across different institutions since certain institutions tend to see sicker patients. Cancer staging helps control for the differences in tumor size, but no attempt is made to control for differences in the overall health of the patient.

In 1996, Piccirillo's team developed the Comorbidity Education Program, which includes a training manual, video and data collection forms. The program incorporates the 27 most common comorbid ailments, including the level of severity of these conditions on a four-point scale -- no disease, mild, moderate or severe. This information is combined with data already being collected by registrars, including tumor size and type.

Cancer registrars trained in this program yielded consistent results when validated by a trained research assistant who evaluated the program's success. The average time spent recording information from medical records only increased by about two minutes per record, and post-program questionnaires revealed that registrars found the coding method relatively simple and easy to learn.

The information gathered over the past several years already is being evaluated. For example, patients with severe comorbidity are almost three times more likely to die than patients with no comorbid ailments, even after controlling for tumor site and size and patient age, race and gender.

Because of the importance of comorbidity information in determining treatment and prognosis, the Commission on Cancer (CoC) recently mandated the collection of this information and the method for its collection. But according to Piccirillo, the CoC's approach, which is based on the ICD-9 coding system used for medical bills, has several key flaws.

First, it does not include information about disease severity. Therefore, an individual with mild diabetes that can be controlled by dietary restrictions receives the same code as an individual with severe diabetes taking daily insulin shots. Medical bills also may omit certain diseases for socio-political reasons (for example, mental illness or AIDS), and often are written with the intent of maximizing reimbursement rather than capturing the most severe comorbidities.

"The COC based their approach on the theory that training registrars on a new coding system is time-consuming and impractical," Piccirillo explains. "But we've taken one example of a new method and we've studied it, we've documented it and we've published it: Cancer registrars can learn comorbidity coding."

Having improved and refined their training protocol during the first several years of its use, the Comorbidity Education Program takes 10 hours to learn. The team currently is finalizing a web-based training program based on their experiences with in-person training seminars. In fact, the National Health Service in London is planning to incorporate this program into its current cancer registry system throughout the United Kingdom.

The program also will be used in the five-year Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) project, sponsored by the National Cancer Institute. This project will enroll 10,000 patients with newly diagnosed lung or colorectal cancers and address how characteristics of patients, providers and the systems delivering care affect what services patients receive for the management of cancer and its consequences.

In addition to training other cancer centers about their program, Piccirillo's team now is working on developing mathematical models that identify important comorbidity elements in elderly cancer patients. Such models may provide a more comprehensive and informative way to determine prognosis for individual elderly cancer patients.
Piccirillo JF, Costas I, Jeffe DB, Spitznagel EL. Development and validation of a cancer comorbidity education program. 2003 Cancer Conference, Sept 16, 2003.

Piccirillo JF, Costas I, Spitznagel EL. The prognostic importance of comorbidity to cancer statistics. 2003 Cancer Conference, Sept. 15, 2003.

Funding from the National Cancer Institute supported this research.

The full-time and volunteer faculty of Washington University School of Medicine are the physicians and surgeons of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked.

Washington University School of Medicine

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to